We are accelerating the promise of gene therapy to liberate patients from chronic and currently incurable diseases.
We strive to translate the promise of gene therapy into effective and accessible products that have the power to restore health and improve lives.
Calimmune is focused on improving the patient experience for stem cell gene therapy by making it an outpatient procedure. Our therapeutic candidates aim to increase efficacy, reduce toxicity, and make these treatments more accessible to patients worldwide.
Our breakthrough Cytegrity™ lentivector manufacturing system for gene therapy is reproducible and scalable.